Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils

Antimicrob Agents Chemother. 1999 Feb;43(2):246-52. doi: 10.1128/AAC.43.2.246.

Abstract

The mechanism of radiolabeled levofloxacin ([3H]levofloxacin) uptake by human polymorphonuclear neutrophils (PMNs) was investigated by a classical velocity centrifugation technique. PMNs were incubated with levofloxacin for 5 to 180 min under various conditions before centrifugation through an oil cushion. Radioactivity was measured in the cell pellet to determine the amount of cell-associated drug. The uptake of levofloxacin was moderate with a cellular concentration/extracellular concentration ratio of about 4 to 6. Levofloxacin accumulated in PMNs parallel to the extracellular concentration, without saturation, over the range of 2.5 to 200 mg/liter (linear regression analysis: r = 0.92; P < 0.001). The activation energy was low (36 +/- 7.2 kJ/mol). Levofloxacin uptake was increased in Ca(2+)-depleted, EGTA-containing medium by approximately 33% (P = 0.022), while Ni2+, a Ca2+ channel inhibitor, inhibited it in a concentration-dependent manner, with the concentration that inhibited 50% of control uptake being approximately 2.65 mM. Verapamil (an L-type Ca2+ channel inhibitor) and other pharmacologic agents which modify Ca2+ homeostasis did not modify levofloxacin uptake. Interestingly, Ca2+ and Mg2+ inhibited levofloxacin uptake in a concentration-dependent manner. EGTA, Ni2+, and verapamil did not modify levofloxacin efflux; thapsigargin, a Ca2+ pool-releasing agent, modestly increased the intracellular retention of levofloxacin. In addition, contrary to other fluoroquinolones, probenecid at 1 to 10 mM did not modify either levofloxacin uptake or efflux. These data are consistent with a mechanism of passive accumulation of levofloxacin in PMNs. Extracellular Ca2+ and Mg2+ may influence the structural conformation of levofloxacin or the lipophilicity of PMN membranes, thus explaining their effect on levofloxacin uptake.

MeSH terms

  • Anti-Infective Agents / metabolism*
  • Calcium / metabolism
  • Chelating Agents / pharmacology
  • Humans
  • Hydrogen-Ion Concentration
  • Kinetics
  • Levofloxacin*
  • Neutrophils / metabolism*
  • Ofloxacin / metabolism*
  • Probenecid / pharmacology
  • Protein Kinase Inhibitors
  • Temperature

Substances

  • Anti-Infective Agents
  • Chelating Agents
  • Protein Kinase Inhibitors
  • Levofloxacin
  • Ofloxacin
  • Probenecid
  • Calcium